Specialty biopharmaceutical company RedHill Biopharma Ltd. (Nasdaq:RDHL) announced on Monday that the Biomedical Advanced Research and Development Authority (BARDA) selected its drug opaganib for development to treat Ebola virus disease.
BARDA will partially fund the advancement of opaganib under a cost-sharing contract to help combat Ebola outbreaks. Opaganib has shown progress through the Animal Rule pathway, enabling potential FDA approval using pivotal animal studies when human trials are not feasible.
In a U.S. Army study, opaganib significantly increased survival in an in vivo Ebola model, marking it as the first host-directed molecule to show activity against the virus. Recent studies also demonstrated a synergistic effect when combined with remdesivir, enhancing potency while maintaining cell viability. Opaganib is being developed for several other indications, including oncology, viral infections and COVID-19.
Federal funds from the Department of Health and Human Services support the project under contract number 75A50124C00059.
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
RevOpsis Therapeutics receives SBIR grant of over USD1.8m
AtomVie Global Radiopharma partners with Radiopharm Ventures
Lipella granted patent for innovative drug delivery technology
Adocia patents stable hormone combinations for obesity and diabetes
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
GSK reports positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial